Bifogade filer
AlzeCure presents ACD440 at the NeuPSIG 2025 pain conference
Martin Jönsson O Märta Segerdahl AlzeCure Pharma
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract with clinical data with the drug candidate ACD440 has been accepted for presentation at the international pain conference NeuPSIG 2025, which will be held this year in Berlin on September 4-6.
The abstract, titled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, will be presented at the international pain conference NeuPSIG 2025 by Märta Segerdal, Head of Development and CMO at AlzeCure Pharma. Other authors are Adriana Miclescu, Ingrid Lönnstedt, Magnus Halldin and Rolf Karlsten.
The presentation includes a further analysis of the clinical study results from the Phase IIa study of ACD440 in patients with chronic peripheral neuropathic pain. The results show that ACD440 has powerful analgesic effects, especially in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440.
ACD440 is a first-in-class TRPV1 antagonist in clinical development as a novel topical treatment for peripheral neuropathic pain. The drug candidate, which was incorporated via a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance to achieve maximum analgesic effect and over a long period of time.
“The fact that we obtain significant analgesic effects of ACD440 in patients with peripheral neuropathic pain, despite the fact that the majority are already treated with other painkillers, demonstrates the therapeutic potential of ACD440,” said Märta Segerdal, Head of Development and CMO at AlzeCure Pharma.
“The positive results from the Phase II study demonstrate both significant efficacy and good tolerability and support the continued development of ACD440. This further strengthens the project, both scientifically and in terms of interest from potential partners, in an area of great medical need and an ongoing opioid crisis," said Martin Jönsson, CEO of AlzeCure Pharma.
The abstract and the poster will be available on AlzeCure’s website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews).